Highlights NervGen Pharma Corp.

Equities

NGEN

CA64082X2032

Market Closed - Toronto S.E. Other stock markets 03:59:59 2024-05-28 pm EDT			5-day change	1st Jan Change
2 ^CAD	-4.76%		-3.85%	-25.93%

Apr. 17	NervGen Reports FY 2023 Net Loss of $0.38 Per Share, Provides Operations Update	MT
Apr. 17	NervGen Pharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

NervGen Reports FY 2023 Net Loss of $0.38 Per Share, Provides Operations Update	Apr. 17	MT
NervGen Pharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 17	CI
NervGen Pharma Closes C$23 Million Bought Deal Financing	Mar. 28	MT
NervGen Pharma Raising C$20.1 Million in Bought-Deal Offering of Share Units	Mar. 21	MT
NervGen Pharma Corp. Plans to Initiate A New Study in Which Subjects Completes Open-Label Nvg-291	Feb. 15	CI
NervGen Pharma Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
NervGen Pharma Corp. Receives Fast Track Designation for NVG-291 for the Treatment of Individuals with Spinal Cord Injury	23-10-23	CI
NervGen Pharma Corp. Announces First Subject Dosed in Landmark Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury	23-09-25	CI
NervGen Pharma Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Nervgen Pharma Corp. Receives Institutional Review Board Approval for Its Phase 1B/2A Proof-Of-Concept Clinical Trial Protocol of Its Proprietary Lead Compound, Nvg-291, in Individuals with Spinal Cord Injury	23-08-08	CI
NervGen Pharma Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
NervGen Pharma Appoints Michael Kelly as President & Chief Executive Officer	23-04-10	MT
NervGen Pharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30	CI
NervGen Pharma Announces Completion of Dosing of All Subjects in Phase 1 Clinical Trial of Proprietary Drug Candidate NVG-291	23-02-14	CI
NervGen Pharma Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Nervgen Pharma Corp. Receives FDA Authorization to Expand Enrollment of Males and Premenopausal Females in Phase 1 Clinical Trial of NervGen's NVG-291	22-10-25	CI
NervGen Pharma Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-10	CI
NervGen Up 3.5% As Secures TSX-V Approval for US$15.2 Million Non-brokered Private Placement	22-07-11	MT
Nervgen Pharma Corp. Receives Approval from the Safety Review Committee to Advance to the Third and Highest Dose Cohort in the Multiple Ascending Dose Portion of Phase 1 Clinical Trial of the Company's Proprietary Lead Compound, NVG-291	22-05-12	CI
NervGen Pharma Corp. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-12	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights NervGen Pharma Corp.

Equities

NGEN

CA64082X2032

Highlights

Filters